Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...

Advancements in AI, multi-omics, and genome editing are transforming life sciences and biotechnology, addressing new ...

According to Nova One Advisor, the global biotechnology market size is calculated at USD 2.79 trillion in 2026 and is ...